Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piia Käyhty

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Medicine|December 30, 2022
Optimized riboswitch-regulated AAV vector for VEGF-B gene therapyReetta A E Eriksson, Tiina Nieminen, Lionel Galibert, et al.
Human Gene Therapy|February 12, 2026
Novel, Stable, and Well-Secreted Single-Chain Fc Forms of Programmed Death-1 Immune Checkpoint Inhibitor Efficiently Block PD-1/PD-L1 InteractionPiia Käyhty, Tiina Nieminen, Amira Hyvönen, et al.
Cytotherapy|April 25, 2024
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturingAnnu Luostarinen, Anssi Kailaanmäki, Vesa Turkki, et al.
Gene Therapy|January 9, 2026
The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized micePiia Käyhty, Tiina Nieminen, Reetta A E Eriksson, et al.
Molecular Therapy. Methods & Clinical Development|April 30, 2020
Development of Large-Scale Downstream Processing for Lentiviral VectorsAnniina J Valkama, Igor Oruetxebarria, Eevi M Lipponen, et al.
Frontiers in Medicine|March 20, 2023
Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapyReetta A E Eriksson, Tiina Nieminen, Lionel Galibert, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Medicine|December 30, 2022
Optimized riboswitch-regulated AAV vector for VEGF-B gene therapyReetta A E Eriksson, Tiina Nieminen, Lionel Galibert, et al.
Human Gene Therapy|February 12, 2026
Novel, Stable, and Well-Secreted Single-Chain Fc Forms of Programmed Death-1 Immune Checkpoint Inhibitor Efficiently Block PD-1/PD-L1 InteractionPiia Käyhty, Tiina Nieminen, Amira Hyvönen, et al.
Cytotherapy|April 25, 2024
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturingAnnu Luostarinen, Anssi Kailaanmäki, Vesa Turkki, et al.
Gene Therapy|January 9, 2026
The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized micePiia Käyhty, Tiina Nieminen, Reetta A E Eriksson, et al.
Molecular Therapy. Methods & Clinical Development|April 30, 2020
Development of Large-Scale Downstream Processing for Lentiviral VectorsAnniina J Valkama, Igor Oruetxebarria, Eevi M Lipponen, et al.
Frontiers in Medicine|March 20, 2023
Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapyReetta A E Eriksson, Tiina Nieminen, Lionel Galibert, et al.
Pageof 1